Global  

Algernon Pharmaceuticals files investigational new drug application with FDA for possible coronavirus treatment Ifenprodil

Proactive Investors Monday, 25 May 2020
Algernon Pharmaceuticals Inc (CSE:AGN) (OTCQB:AGNPF) submitted an investigational new drug application to the US Food and Drug Administration for the next phase of its multinational study of lead drug NP-120, known as Ifenprodil. The drug, an NMDA receptor antagonist, is a potential therapy for patients with COVID-19, the disease caused by coronavirus. Ifenprodil could reduce the infiltration of neutrophils and T-cells into the lungs, where they can release glutamate and cytokines respectively. The latter can result in the highly problematic cytokine storm that contributes to the loss of lung function, and ultimately death, in COVID-19 patients.  READ: Algernon Pharmaceuticals moving closer to Ifenprodil trials for coronavirus treatment as it seeks ethics approval in Australia As an N-methyl-D-aspartate (NMDA) receptor antagonist that targets the NMDA-type subunit 2B (Glu2NB), Ifenprodil prevents glutamate signaling. The NMDA receptor is found on many tissues including lung cells and T-cells, neutrophils. Phase 2b/3 will start with an aggregate of 100 patients and, assuming positive preliminary data, will move into Phase 3. The data will determine the number of patients necessary to reach statistical significance. All patients enrolled in the trial will be randomized in a one-to-one manner and be treated with an existing standard of care. A randomly selected group will also be given a 20 milligram dose of Ifenprodil three times a day over a two-week period. Doctors will observe patient outcomes in a number of categories, such as mortality, blood oxygen levels, length of time in intensive care and time to mechanical ventilation. Vancouver-based Algernon has already received the go-ahead to commence Phase 2b/3 in Canada and filed for ethics approval in Australia. “We have already started communicating with a number of US based research institutions in advance, to make sure that we can move quickly with the U.S. part of the clinical trial, if approved,” said Christopher Moreau, CEO of Algernon Pharmaceuticals. “We have identified strong interest to participate in the study and we look forward to starting the trial as soon as possible.” The company told shareholders that it is not making any express or implied claims that Ifenprodil is effective for the treatment of acute lung injury, COVID-19 or any other medical condition. Contact Angela at [email protected] Follow her on Twitter @AHarmantas
0
shares
ShareTweetSavePostSend
 

You Might Like


Related videos from verified sources

WBZ Evening News Update For May 14 [Video]

WBZ Evening News Update For May 14

Nearly 1,700 new coronavirus cases in Massachusetts, 167 new deaths; Gov. Baker announces ambitious new coronavirus testing goal; Mass unemployment claims drop; Severe weather possible Friday.

Credit: WBZ CBS Boston     Duration: 02:42Published
Hundreds Of Military Service Members Fighting Coronavirus Pandemic In NYC [Video]

Hundreds Of Military Service Members Fighting Coronavirus Pandemic In NYC

The USNS Comfort has left and the Javits field hospital is no more, but the military still has boots on the ground in New York City. CBS2's Lisa Rozner got an inside look through the eyes of an Air..

Credit: CBS 2 New York     Duration: 02:05Published
Long Island Duck Farmers Struggling, But Adapting To Business Amid Coronavirus Pandemic [Video]

Long Island Duck Farmers Struggling, But Adapting To Business Amid Coronavirus Pandemic

The earth has shifted under New York's farm-to-table supply chain. Farmers of an iconic staple, Long Island Duck, are struggling but adapting; CBS2's Jennifer McLogan reports.

Credit: CBS 2 New York     Duration: 01:52Published

Related news from verified sources

Algernon Pharmaceuticals moving closer to Ifenprodil trials for coronavirus treatment as it seeks ethics approval in Australia

Algernon Pharmaceuticals Inc (CSE:AGN) (OTCQB:AGNPF) said it is seeking ethics approval in Australia for its planned multinational Phase 2b/3 study of its...
Proactive Investors

Algernon Pharmaceuticals closes special warrants offering that raised nearly C$7M

Algernon Pharmaceuticals Inc (CSE: AGN) (OTCQB:AGNPF) announced Wednesday it closed a private placement offering of special warrants that raised nearly C$7...
Proactive Investors


Tweets about this